We are happy to announce that we now have started developmentof type 1 diabetes tissue therapeutics based on induced pluripotent stem cells(IPSC). The cells are derived from human skin fibroblasts and are programmed todevelop into insulin-producing beta cells.
We have performed initial trials using the cells to evaluatecompatibility with our Biopixlar bioprinting technology and our in vivo-testedbiomaterials that we use to construct implants. To test our ability to print theIPSCs on the selected biomaterials, we created cell squares with a 500 µm side length, built in a uniform array. We are happy to report that the cells printvery well and that we are able to produce highly confluent cell patches with clearlydefined features using our Nexocyte methodologies.
The next step that we now are embarking on is to perform studiesto determine insulin release from IPSC-containing implants and to furtheroptimize implant construction to prepare for in vivo testing.
Fluicell’s CEO Carolina Trkulja comments
"I am very pleased to announce that we continue to make progress in our development of tissue-based therapy for type 1 diabetes.The transition to using stem cells in our implants means that we are taking another step towards our goal of creating a treatment solution that is ready for clinical trials. Our initial studies have shown good compatibility with the Nexocyte platform, and we have high hopes for the insulin secretion studies that we are now initiating."